BiotechTube

Lexiscan

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cardiovascular Diseases

Conditions

Cardiovascular Diseases, Coronary Artery Disease

Trial Timeline

Feb 9, 2016 → Jun 14, 2018

NCT ID
NCT03103061

About Lexiscan

Lexiscan is a phase 2 stage product being developed by Astellas Pharma for Cardiovascular Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT03103061. Target conditions include Cardiovascular Diseases, Coronary Artery Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT03103061Phase 2Completed
NCT01085201Phase 1Completed

Competing Products

20 competing products in Cardiovascular Diseases

See all competitors
ProductCompanyStageHype Score
Dulaglutide + PlaceboEli LillyPhase 3
77
raloxifene + placeboEli LillyPhase 3
77
EvacetrapibEli LillyPhase 1
33
Orforglipron + PlaceboEli LillyPhase 3
77
Prasugrel (CS-747) + ClopidogrelEli LillyPhase 2
52
Rosuvamibe + MonorovaYuhanApproved
85
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
85
Rosuvamibe + MonorovaYuhanApproved
85
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
85
mirabegron + tamsulosinAstellas PharmaPhase 1
33
TRC150094Torrent PharmaceuticalsPhase 1/2
41
Lorcaserin hydrochloride + PlaceboEisaiApproved
85
Lepodisiran Sodium + PlaceboEli LillyPhase 3
77
Retatrutide + PlaceboEli LillyPhase 3
77
Empagliflozin + PlacebosEli LillyApproved
85
Evacetrapib + PlaceboEli LillyPhase 3
77
Placebo + AZD0780AstraZenecaPhase 2
52
Risk of low dose aspirin discontinuationAstraZenecaPre-clinical
23
Midazolam + AZD5718AstraZenecaPhase 1
33
14C]AZD4831 Oral SolutionAstraZenecaPhase 1
33

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85